Patents by Inventor Sentob Saragosti
Sentob Saragosti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8227185Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: GrantFiled: April 24, 2009Date of Patent: July 24, 2012Assignee: Institute National de la Sante et de la Recherche Medical-InsermInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Publication number: 20100184014Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: ApplicationFiled: April 24, 2009Publication date: July 22, 2010Inventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Patent number: 7534877Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBE30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: GrantFiled: September 15, 2005Date of Patent: May 19, 2009Assignees: Institute National de la Sante et de la Recherche Medicale-Inserm, Assitance Publique-Hopitaux de Paris, Institut PasteurInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Publication number: 20070190524Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: ApplicationFiled: September 15, 2005Publication date: August 16, 2007Inventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Patent number: 7030234Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: GrantFiled: November 22, 2002Date of Patent: April 18, 2006Assignees: Institute National de la Sante et de la Recherche Medicale-Inserm, Assistance Publique-Hopitaux de Paris, Institute PasteurInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Publication number: 20030157660Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent.Type: ApplicationFiled: November 22, 2002Publication date: August 21, 2003Applicant: Institute National de la Sante et de La Recherche Medicale-InsermInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Patent number: 6509018Abstract: The invention provides peptides which are expressed by the env gene of a non-M, non-O HIV-1 virus, in particular a strain designated YBF30. The invention also provides fragments of the peptides that including the V3 loop region and their corresponding nucleotide sequences. The invention further provides kits including diagnostic reagents containing these molecules or immunogenic compositions containing these peptides, as well as methods for screening and typing non-M, non-O HIV-1 viruses and HIV-1 viruses expressing these peptide and/or nucleotide sequences.Type: GrantFiled: August 27, 1999Date of Patent: January 21, 2003Assignee: Institute National de la Sante et de la Recherche Medicale-InsermInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Patent number: 6270975Abstract: Group HIV-1 retrovirus strains, particularly the strains known as BCF02, BCF01, BCF06, BCF07, BCF08, BCF11, BCF03, BCF09, BCF12, BCF13 and BCF14, fragments of said retroviruses, and the uses thereof as a diagnostic reagent and as an immunogen, are disclosed.Type: GrantFiled: November 22, 1999Date of Patent: August 7, 2001Assignees: Institut National de la Sante et de la Recherche Medicale-Inserm, Assistance Publique-Hopitaux de ParisInventors: François Simon, Sentob Saragosti, Ibtissam Loussert-Ajaka, Thoai-Duong Ly, Marie-Laure Chaix-Baudier
-
Patent number: 6030769Abstract: Group HIV-1 retrovirus strains, particularly the strains known as BCF02, BCF01, BCF06, BCF07, BCF08, BCF11, BCF03, BCF09, BCF12, BCF13 and BCF14, fragments of said retroviruses, and the uses thereof as a diagnostic reagent and as an immunogen, are disclosed.Type: GrantFiled: December 1, 1997Date of Patent: February 29, 2000Assignees: Institut National de la Sante et de la Recherche Medical-Inserm, Assistance Publique-Hopitaux de ParisInventors: Fran.cedilla.ois Simon, Sentob Saragosti, Ibtissam Loussert-Ajaka, Thoai-Duong Ly, Marie-Laure Chaix-Baudier